 |
Hubei Honest Biochemical Co., Ltd. |
|
||||||
Quick details:
Cardarine,GW-501516
Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds;kl;Inhibitor;
Antineoplastic;SARMs(Selective androgen receptor modulator)
Assay: 98.0%--102.0%. USP32
CAS: 317318-70-0
M.F.: C21H18F3NO3S2
M.W.: 453.5
M.P.: 134-136°C
Appearance:White powder
Synonyms:
2-(4-((2-(4-(TRIFLUOROMETHYL)PHENYL)-5-METHYLTHIAZOL-4-YL)METHYLTHIO)-2-METHYLPHENOXY)ACETIC ACID;2-[2-Methyl-4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]thio]phenoxy]acetic Acid;Methyl-methyl-trifluoromethylphenyl -thiazolyl-methylsulfanyl-phenoxy-acetic Acid;2-(4-((2-(4-(trifluoromethyl)phenyl)-4-methylthiazol-5-yl)methylthio)-2-methylphenoxy)acetic acid;GW 1516;2-(2-methyl-4-((5-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-4-yl)methylthio)phenoxy)acetic acid;GW501516, Free Acid;GSK-516
Product description:
GW 501516 (Cardarine) is one of the most versatile performance enhancers one will ever come across.
Whether you are looking to drastically increase endurance, melt fat, cut or recomp, GW will truly shine. There is a place for GW in every cycle, regardless of the desired goal.
It can only add extra benefits that will further enhance the chances of accomplishing goals and maximizing gains
GW-501516 is a unique medication officially classified as a PPAR receptor agonist (PPAR-RA). Research for this medication began in 1992 in a conjoined effort between GlaxoSmithKline (GSK) and Ligand Pharmaceuticals. Research into this product was set forth in an effort to provide treatment for various cardiovascular diseases, as well as diabetes, obesity and other conditions. It was soon discovered that the PPAR-RA was highly effective at enhancing endurance, but it was also shown to carry a high potential cost. It was discovered that GW-501516 increased the chances of cancer significantly, and as a result, GSK dropped all further research. However, the studies that produced cancerous results used doses of GW-501516 that were 500 to even 1000 times the amount that a human being would take. If cancer is a risk with standard dosing is unknown.
Usage: It had been investigated as a potential treatment for obesity, diabetes, dyslipidemia and cardiovascular disease. GW501516 could be used by athletes as an ergogenic performance enhancing
How it works?
ENDUROBOL is a selective agonist (activator) of the PPARδ receptor. It displays high affinity (Ki = 1 nM) and potency (EC50 = 1 nM) for PPARδ with > 1000 fold selectivity over PPARα and PPARγ.
It activates AMP-activated protein kinase and stimulates glucose uptake in skeletal muscle tissue, and GW 501516 has been demonstrated to reverse metabolic abnormalities in obese men with pre-diabetic metabolic syndrome, most likely by stimulating fatty acid oxidation. It has been proposed as a potential treatment for obesity and related conditions, especially when used in conjunction with a synergistic compound AICAR, as the combination has been shown to significantly increase exercise endurance in human.
